Literature DB >> 27500120

Intensified intravitreal bevacizumab treatment regime for type 1 and 2 idiopathic macular telangiectasia.

Christos Chryssafis1, Aljoscha Steffen Neubauer2, Efstathios Papadopoulos1, Kai Januschowski1, Karl Thomas Boden1, Peter Szurman3.   

Abstract

Entities:  

Year:  2016        PMID： 27500120      PMCID： PMC4951666          DOI： 10.18240/ijo.2016.07.23

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  11 in total

1.  Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia.

Authors:  K Takayama; S Ooto; H Tamura; K Yamashiro; A Otani; A Tsujikawa; N Yoshimura
Journal:  Eye (Lond)       Date:  2010-04-30       Impact factor: 3.775

2.  Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2.

Authors:  G Matt; S Sacu; C Ahlers; C Schütze; R Dunavoelgyi; F Prager; C Pruente; U Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2010-09-24       Impact factor: 3.775

3.  Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.

Authors:  Raja Narayanan; Jay Chhablani; Manish Sinha; Vivek Dave; Mudit Tyagi; Rajeev R Pappuru; Baruch D Kuppermann
Journal:  Retina       Date:  2012 Nov-Dec       Impact factor: 4.256

4.  Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors:  Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-29       Impact factor: 3.117

5.  Bevacizumab in the treatment of idiopathic macular telangiectasia.

Authors:  Maria-Andreea Gamulescu; Andreas Walter; Helmut Sachs; Horst Helbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

6.  Long-term course in type 2 idiopathic macular telangiectasia.

Authors:  Tobias Meyer-ter-Vehn; Sina Herzog; Marc Schargus; Winfried Göbel; Rainer Guthoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-25       Impact factor: 3.117

7.  Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.

Authors:  P Charbel Issa; R P Finger; F G Holz; H P N Scholl
Journal:  Br J Ophthalmol       Date:  2008-07       Impact factor: 4.638

8.  Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.

Authors:  Jaclyn L Kovach; Philip J Rosenfeld
Journal:  Retina       Date:  2009-01       Impact factor: 4.256

9.  [Intravitreal bevacizumab in the treatment of idiopathic juxtafoveal telangiectasis type I].

Authors:  A García-Ben; F Gómez-Ulla; M J Rodriguez-Cid
Journal:  Arch Soc Esp Oftalmol       Date:  2013-04-10

10.  Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.

Authors:  Eric J Sigler; John C Randolph; Jorge I Calzada; Steve Charles
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-06       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.